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Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely
unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been associated with PRCa. Many
candidate genes have been suggested to be involved in PRCa, such as those that are central to cellular growth and differentiation in
the prostate gland. The vitamin D receptor (VDR) and CYP3A4 have been shown to be involved in the regulation of cell proliferation
and differentiation in prostate cells. Genetic variations of these genes have been associated with PRCa in case–control studies and
may be useful to detect BPH patients that have a higher risk of developing PRCa. The association between CYP3A4 and VDR TaqI
SNPs and the risk of developing PRCa have been investigated in this study by determining the variant genotype frequencies of both
SNPs in 400 patients with BPH who have been followed clinically for a median of 11 years. The results of this study showed that the
incidence rate of PRCa was higher in BPH patients having CYP3A4 variant genotype compared to those with wild type (relative risk
(RR)¼2.7; 95% CI¼0.77–7.66). No association between variant genotype and risk of developing PRCa was observed with the VDR
TaqI variant genotype. In addition, the results of combined genotype analysis of these two SNPs showed a borderline significant
association between CYP3A4 and VDR TaqI combined variant genotypes and PRCa risk (RR¼3.43; 95% CI¼0.99–11.77). While
independent confirmation is required in further studies, these results provide a potential tool to assist prediction strategies for this
important disease.
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Prostate cancer (PRCa) constitutes a major health issue worldwide.
Prostate cancer is one of the most common causes of cancer death
in men (Parker et al, 1996; Prior and Waxman, 2000). The
incidence of PRCa increases with age and it is estimated that 80%
of men would be affected by the age of 80 years (Holund, 1980).
The aetiology of PRCa is unclear, although current evidence
suggests that PRCa is the result of multiple factors that include
ethnicity, environmental, genetics, hormonal and dietary factors
(Pienta and Esper, 1993; Whittemore et al, 1995; Wingo et al, 1996;
Hsieh et al, 1999; Tzonou et al, 1999; Lichtenstein et al, 2000).
Benign prostatic hyperplasia (BPH) is a non-neoplastic enlarge-
ment of the prostate. Benign prostatic hyperplasia is extremely
common, with a rapid increase in prevalence in the fourth decade
of life. According to epidemiological studies, most cancers are
associated with BPH elsewhere in the prostate (83.3%; Carter and
Coffey, 1990; Bostwick et al, 1992) and approximately 3–20% of
patients who have undergone transurethral prostatectomy (TURP)
or open prostatectomy for BPH subsequently develop PRCa
(Armenian et al, 1974; Schwartz et al, 1986; Bostwick et al,
1992). Compared to men without BPH, those with the condition
have a five-fold raised risk of developing PRCa and a four-fold
raised risk of death from PRCa (Armenian et al, 1974). A previous
study reported that a family history of prostate disease (PRCa or
BPH) was more frequently seen in relatives of men with BPH
(20%) than in relatives of men with PRCa (12.8%) or in healthy
controls (5.1%) (Schuman et al, 1977). In addition, in vitro
malignant transformation of BPH tissue has been previously
reported (Chen and Heidelberger, 1969; Fraley et al, 1970; Frank
and Wilson, 1970). These results suggest that common genetic
mechanisms may predispose to benign and malignant prostate
disease. Moreover, these results suggest that BPH may be part of a
premalignant environmental condition in the prostate gland. With
the increasing incidence of PRCa in many populations, there is an
urgent need for the identification of molecular markers that can
serve as indicators of disease risk to focus chemoprevention and
early detection strategies. Many candidate PRCa genes have been
suggested, including genes influencing cellular growth and
differentiation. The cytochrome P450 3A4 enzyme (CYP3A4) is a
member of the human P450 family. CYP3A4 protein is responsible
for hydroxylation of testosterone, which results in the deactivation
of the hormone function (Waxman et al, 1988; Yamazaki and
Shimada, 1996). A single-nucleotide polymorphism (SNP) in the
CYP3A4 promoter ( 290 A to G) was previously reported with
two CYP3A4 alleles; CYP3A4
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(Rebbeck et al, 1998; Sata et al, 2000). The functional influence of
this SNP is unclear, but initial in vitro and in vivo studies suggest a
role in transcriptional control leading to altered CYP3A4 enzyme
activity for a number of substrates, including testosterone
(Amirimani et al, 1999; Rebbeck, 2000; Wandel et al, 2000).
Genetic epidemiology studies found that the CYP3A4*1B allele was
associated with higher clinical stage and grade of PRCa (Rebbeck
et al, 1998; Paris et al, 1999; Kittles et al, 2002). The CYP3A4*1B
allele frequency has been shown in various studies to vary
markedly between ethnic groups and match solely with the
incidence of PRCa based on ethnicity (Walker et al, 1998; Ball
et al, 1999; Paris et al, 1999; Sata et al, 2000; Tayeb et al, 2000;
Kittles et al, 2002). The highest incidence of PRCa was found in
African Americans, intermediate in Caucasians, and the lowest in
Asians (Pienta and Esper, 1993; Wingo et al, 1996). Vitamin D has
been implicated in PRCa, with several epidemiological studies
linking low vitamin D levels with increased risk of PRCa
(Schwartz and Hylka, 1990; Corder et al, 1993). Calcitriol, the
biologically active metabolite of vitamin D, 1,25-dihydroxyvitamin
D3, has been shown to inhibit prostate cell growth (Skowronski
et al, 1993; Hedlund et al, 1996). The action of vitamin D is
mediated through binding to its nuclear receptor (VDR). The
inherited TaqI SNP in exon 9 of the VDR 30UTR regions (C352T)
has been demonstrated to affect vitamin D levels (Morrison et al,
1994; Ma et al, 1998). Previous studies observed an association
between the TaqI SNP and PRCa risk (Taylor et al, 1996; Correa-
Cerro et al, 1999; Hamasaki et al, 2001). Our previous nested
case–control association studies found that the frequencies of
the CYP3A4*1B and VDR TaqI TT genotypes are higher among
BPH patients who subsequently develop PRCa than among
BPH control patients (Odds ratio, OR: 5.2 and 5.16, respectively;
Tayeb et al, 2002 submitted). Moreover, we found that the
frequency of CYP3A4*1B and VDR TT combined genotypes is
increased in BPH patients who developed PRCa later on in
their life compared with BPH patients who did not, and the risk
of developing PRCa was 13-fold higher in BPH patients having
the CYP3A4*1B and VDR TT combined genotypes than the
control (Tayeb et al, 2002, submitted). The association between
CYP3A4 and VDR TaqI SNPs, and the risk of developing
PRCa in BPH patients have been investigated further in this
study by determining the CYP3A4*1B and VDR TT genotype
frequencies in 400 patients with BPH who have been followed up to
11 years.
MATERIALS AND METHODS
Data for BPH patients from years 1989 to 1990 (Northeast
Scotland; Grampian region) were collected using the University
of Aberdeen Department of Pathology data bases. In total, 1010
samples were identified. Data for PRCa from years 1989 to April
2000 were also collected and 44 of the 1010 BPH patients (4.4%)
subsequently developed PRCa in the period 1989–April 2000. The
geographic region has very little population migration over
generations and is served by a single pathology department. Of
the 1010 BPH samples, 400 were randomly selected for further
molecular analysis, of which 21 had subsequently developed PRCa
(5%). All sections were rereviewed by pathologist to confirm the
diagnosis.
Genotyping
DNA was extracted from formalin-fixed, paraffin-embedded
tissues. The tissue sections were deparaffinised with xylene and
ethanol, and then DNA was isolated by proteinase K digestion
(Frank et al, 1996). A 289bp fragment CYP3A4*1B was amplified
by PCR and screened using single-strand conformation poly-
morphism (SSCP) analysis (Tayeb et al, 2000). Previously
described primer set was used to amplify the region of 198bp
around the VDR TaqI polymorphic region (Lundin et al, 1999).
Genomic DNA (100–500ng) was subjected to PCR amplification in
a2 5 ml reaction mixture containing 10 PCR buffer (MBI,
Sunderland, UK), 1mM MgCl2 (MBI), 200mM dNTP mix (Bioline,
London, UK), 10pmol of each primer, 1U of Taq polymerase
(Roche, Lewes, UK), and sterilised distilled water. The genomic
DNA was initially denatured at 941C for 2min and thereafter
subjected to 35 cycles of PCR amplification with denaturation
for 1min at 941C, annealing for 2min at 601C, extension for
2min 30s at 721C, and a final extension step at 721C for 10min.
The PCR products were digested with the TaqI restriction
endonuclease (Roche, Lewes, UK) at 651C for 5h. Genotypes for
the SNPs were determined after separation on a 3% agarose gel.
Individuals were scored as TT homozygous (absence of TaqI
restriction sites), Tt heterozygotes, or tt (presence of TaqI
restriction sites).
Statistical analysis
Random selection for cohort samples was made using Minitab
software version 12.1. The incidence rate and the relative risk (RR)
of developing PRCa with studied markers and the power of the
cohort study were calculated using Stata 1.0 software.
RESULTS
CYP3A4*1B frequencies across populations
Our cohort study had 83% power to detect an RR of 4. The overall
incidence rate of PRCa in this study was 645 per 100000 men-year.
Genotype frequencies of the CYP3A4 SNP in the cohort population
are shown in Table 1. From Table 1, the frequencies of the
CYP3A4*1B homozygote and heterozygote genotypes were higher
in BPH patients who developed PRCa during the time of follow-up
compared to BPH patients who did not. Genotype frequencies of
CYP3A4 SNP and incidence rate of PRCa in the cohort study are
shown in Table 2. From Table 2, the incidence rate of PRCa was
higher in BPH patients with CYP3A4*1B genotype compared to
BPH patients with CYP3A4*1A homozygotes. The RR of develop-
ing PRCa was 2.7 (95% CI¼0.77–7.66) in BPH patients having a
CYP3A4*1B genotype.
VDR TT genotype frequency across population
The power of the cohort study was predicted to detect an RR
of 4 with 82% power. Genotype frequencies of the TaqI SNP in
the cohort population are shown in Table 3. From Table 3,
the frequency of the TT genotype is similar in BPH patients
Table 1 Distribution of CYP3A4 genotype frequencies in the cohort
population
Genotype frequency (%)
Population n A/A A/G G/G
Benign prostatic hyperplasia patients
developing PRCa during
follow-up period
21 16 (76) 4 (19) 1 (5)
Benign prostatic hyperplasia patients
not developing PRCa during
follow-up period
379 344 (91) 35 (9) 0 (0)
n=number of subjects, A/A (homozygote wild type; CYP3A4*1A/CYP3A4*1A), A/G
(heterozygote; CYP3A4*1A/CYP3A4*1B) and G/G (homozygote variant; CYP3A4*1B/
CYP3A4*1B).
CYP3A4, VDR and PRCa
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36%, respectively). The incidence rate of PRCa was lower
in BPH patients with TT genotype compared to BPH patients
with Tt or tt genotypes (Table 4). The RR of developing
PRCa was 0.86 (95% CI¼0.29–2.28) in BPH patients
having a TT genotype. However, the results were not statistically
significant.
Combined genotype analysis
The frequencies of the CYP3A4*1B homozygote, heterozygote
(A/G and G/G), and VDR TT combined genotypes were higher
in BPH patients who developed PRCa during the time of
follow-up compared to BPH patients who did not (Table 5). The
incidence rate of PRCa was higher in BPH patients with
CYP3A4*1B (A/G and G/G) and VDR TT combined genotypes
compared to BPH patients with other combined genotypes
(Table 6). The RR of developing PRCa was 3.43 (95% CI¼0.99–
11.77) in BPH patients having a CYP3A4*1B and VDR TT
combined genotypes.
DISCUSSIONS
Both PRCa and BPH are common diseases for which the incidence
increases with age. Previous studies have defined a significant
association between BPH and developing PRCa (Armenian et al,
1974; Bostwick et al, 1992). With the increasing incidence of BPH
in the ageing population, there is an urgent need for the
identification of molecular markers that can serve as prognostic
indicators for developing PRCa in those patients with BPH.
Germline and somatic variations in genes directly involved in the
regulation of prostate cell growth might be critically important in
understanding the carcinogenesis of PRCa, as these variants might
be used as diagnostic, prevention, and prognostic markers for
PRCa. The primary aim of this study was to identify molecular
markers that are important in the development of PRCa in patients
with BPH. If molecular markers in patients with BPH are shown to
be predictors for eventually developing PRCa, then more intensive
surveillance and/or early treatment could be offered to those
selected patients. Such an approach is also likely to lead to
improvements in survival. In the converse situation, those patients
who do not have a high risk of developing PRCa could be offered
standard follow-up monitoring. Our previous nested case–control
association studies showed that a constitutive CYP3A4 and VDR
TaqI SNPs are associated with a group of men with BPH who are at
an increased risk of PRCa (Tayeb et al, 2002, submitted). The
association between these two SNPs and risk of developing PRCa
have been investigated further in this study by determining the
CYP3A4*1B and VDR TT genotype frequencies in 400 patients with
BPH (1989–1990). The median years of follow-up for these
patients were 11 years and during the time of follow-up, 21 BPH
patients developed PRCa. The results of this study showed that the
incidence rate of PRCa was higher in BPH patients having a
CYP3A4*1B genotype compared to those homozygous for
CYP3A4*1A, but it was not statistically significant. The RR of
BPH patients developing PRCa was 2.7, although results failed to
reach significance at the 5% level. Regarding VDR TaqI SNP, the
Table 2 Distribution of CYP3A4 genotype frequencies and incidence
rate of PRCa in the cohort population
CYP3A4 SNP genotypes
A/A A/G and G/G
Benign prostatic hyperplasia patient who
developed PRCa during follow-up
16 (76%) 5 (24%)
Person-years of follow-up 2918 340
Incidence rate of PRCa per 100000
men-year
548 1471
Table 3 Distribution of TaqI genotype frequencies in the cohort
population
Genotype frequency (%)
Population n TT Tt tt
Benign prostatic hyperplasia
patient developed PRCa during
follow-up
21 7 (33) 10 (48) 4 (19)
Benign prostatic hyperplasia
patient who did not develop
PRCa
379 136 (36) 181 (48) 62 (16)
n=number of subjects.
Table 4 Distribution of TaqI genotype frequencies and incidence rate of
PRCa in the cohort population
TaqI SNP genotypes
TT Tt and tt
Benign prostatic hyperplasia patient who
developed PRCa during follow-up
7 (33%) 14 (67%)
Person-years of follow-up 1198 2060
Incidence rate of PRCa per 100000 men-
years
584 680
Table 5 Distribution of CYP3A4 and VDR TaqI combined genotype
frequencies in the cohort population
Genotype frequency (%)
Population n A/G G/G and TT Other
Benign prostatic hyperplasia patients
developing PRCa during follow-up
period
21 3 (14) 18 (86)
Benign prostatic hyperplasia patients
not developing PRCa during
follow-up period
379 13 (3) 366 (97)
n=number of subjects, other=other combined genotypes.
Table 6 Distribution of CYP3A4 and VDR TaqI genotype frequencies and
incidence rate of PRCa in the cohort population
CYP3A4&VDR TaqI SNPs genotypes (%)
A/G, G/G and TT Other
Benign prostatic hyperplasia
patient who developed
PRCa during follow-up
3 (14) 18 (86)
Person-years of follow-up 151 3107
Incidence rate of PRCa per
100000 men-years
1987 579
Other=other combined genotypes.
CYP3A4, VDR and PRCa
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TT genotype, although results were not statistically significant.
This lack of significance could be because of the limited power of
the cohort study, as the power of the study was determined to
detect an RR of 4 with 83 and 82% for CYP3A4 and VDR TaqI
SNPs, respectively. The power of a cohort study depends on several
factors: (1) the number of subjects enrolled in the cohort, (2) the
time for which each subject is followed-up, (3) the rate at which
events (PRCa) occur in the cohort, (4) the frequency of ‘exposure’
to the hypothesised risk factor in the cohort (in this case, the
frequency of the CYP3A4 genotypes or/and VDR TaqI genotypes,
which had been hypothesised to be associated with increased risk
of developing PRCa), (5) the size of RR which the investigator want
to detect. As these factors change, the power of the study, or the
necessary sample size, also changes. PRCa is likely to be caused by
complex interactions between genetic, endocrine, and environ-
mental factors. Ethnic differences in the risk of developing PRCa
suggest that in addition to environmental factors, common genetic
variants with low penetrance and high population attributable risk
may play an essential role in the aetiology of PRCa. This study
examined the data for gene–gene interactions between putative
risk genotypes, CYP3A4*1B and VDR TT. These genetic variations
confer an increased risk for the development of PRCa through
their mediation of prostate cell growth and differentiation. The
identification of evidence of a significant interaction (patients with
both risk genotypes) may not necessarily indicate that the two
genes are synergistic. They may instead influence risk via
independent mechanisms. Gene–gene interactions might be
important for the development of PRCa and this interaction needs
to be explored. The results of this study showed that BPH patients
who subsequently developed PRCa have significantly different
frequency of harbouring CYP3A4, and VDR at risk genotypes than
those BPH patients who did not develop PRCa (13-fold, Tayeb et al,
2002, submitted). It is interesting to notice that the ORs obtained
from these combined genotypes (A/G and TT) were higher than
those ORs obtained from each individual variant: 5.2 and 5.16 for
heterozygous CYP3A4*1B and homozygous VDR TT, respectively
(Tayeb et al, 2002, submitted). This study observed a borderline
significant association between these combined genotypes and
PRCa risk (RR¼3.43; 95% CI¼0.999–11.770). The RRs for
these combined genotypes were higher than those obtained for
each individual marker: 2.7 and 0.86 for heterozygous and
homozygous CYP3A4*1B, and homozygous VDR TT, respectively.
Calcitriol has been reported to inhibit PRCa proliferation
and to promote a more differentiated phenotype. VDR, TaqI SNP
has been demonstrated to affect transcriptional activity and mRNA
stability, thus altering the abundance of VDR, and in turn affects
vitamin D level (Morrison et al, 1994). In addition, higher levels of
calcitriol have been reported in those who are homozygous for the
t( TaqI site) allele relative to those who are homozygous for the T
(no site) allele (Morrison et al, 1994; Ma et al, 1998). It has been
speculated that men with the CYP3A4*1B genotype may have
altered testosterone metabolism, promoting androgen-mediated
prostate carcinogenesis and the occurrence of PRCa (Rebbeck et al,
1998). It might be that BPH patients harbouring both CYP3A4 and
VDR TaqI combined risk genotypes have a higher level of
androgen hormones and lower level of calcitriol, which might
lead to an increase in prostate cell growth and reduce the level of
differentiation and apoptosis, which might result in the occurrence
of PRCa. However, larger studies are clearly needed to confirm
these assumptions. If confirmed, the genetic risk factors examined
in this study (VDR, and CYP3A4) are among the strongest risk
factors yet identified for PRCa. The finding of this study is
consistent with a multigenic model of PRCa, where PRCa risk is
influenced by gene–gene and gene–environment interactions. On
the basis of the joint effect of several loci, one might ultimately be
able to construct a risk profile that could predict the development
of the disease and could allow for a more meaningful decision
making regarding optimal treatment strategies.
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